This page tells you about preventing graft versus host disease (GVHD). You can find out about
Your transplant specialist will make sure your donor is as closely matched to you as possible. This helps reduce your risk of GVHD. It is the difference in tissue type between you and your donor that is responsible for the development of GVHD. The HLA (human leukocyte antigen) system describes the proteins found on your blood cells. Your doctors will aim to find a donor with the closest HLA match possible.
Doctors usually test for 5 pairs of major HLA antigens. This gives a total of 10 antigens. We inherit one half of the pair from each of our parents. When choosing a donor, doctors aim to match 10 out of 10 HLA proteins. But it may be possible to do a transplant if they don't all match.
Because we inherit the proteins from our parents, your best chance of a match is with a relative. You have a 1 in 4 (25%) chance of an exact match if you have a brother or sister.
If you don’t have a brother or sister, or they don’t match your tissue type, it may be worth testing other members of the family. Parents especially may be a close enough match. If you still don’t have a match, your doctor will search for a bone marrow match on a register of the general population. Registers are kept by the British Bone Marrow Registry (NHSBT) and the Anthony Nolan Trust. Another possibility is to look at cord blood registries. These contain blood taken from umbilical cords at births, which can be used as a source of stem cells.
Both before and after a transplant doctors use treatments to reduce the chance of GVHD. These treatments destroy T cells. T cells are white blood cells that are part of the immune system. They attack cells that are foreign to the body. So reducing the number of T cells in the donor marrow or stem cells (the graft) reduces GVHD. But sometimes having GVHD is a good thing. The T cells in the graft will also attack any remaining cancer cells, and reduce the risk of your disease coming back. This is called the graft versus disease effect. So doctors try to strike a balance between preventing severe GVHD, and getting some possible benefits from mild GVHD.
Treatments used to prevent GVHD include
- Treatment before your transplant
- Removing T cells from the marrow or stem cells
- Treatment after transplant
You will have a drug called ciclosporin (also called Deximune, Neoral or Sandimmum). This drug works by reducing the number of T cells in your donated marrow or stem cells. You start having it by drip (intravenously) a couple of days before your transplant. Before you go home you start taking it daily as a capsule. You should never take it with grapefruit or grapefruit juice because this can change the way the drug works. You usually keep taking ciclosporin for about 6 months after the transplant. You can find information about the side effects of ciclosporin in the section about drugs for GVHD.
An alternative to ciclosporin, especially if it causes too many side effects for you, is a combination of mycophenolate mofetil (MMF) and tacrolimus. You can find out more about these in the section about drugs for GVHD.
You might have treatment with other drugs before your transplant. This could be alemtuzumab (Campath) or antithymocytic globulin (ATG). Newer drugs being tried include tacrolimus or sirolimus (Rapamide). These drugs target and destroy your existing T cells and the new T cells you make after your transplant. This helps prevent you rejecting the donor marrow or stem cells as well as reducing your chances of developing GVHD.
Your doctors can remove T cells from your donor’s bone marrow after it has been donated, or during the donation of stem cells. These methods are not commonly used. This is called T cell depletion.
You will also have treatment with drugs after your transplant to reduce the risk of GVHD. You might have some low doses of the chemotherapy drug methotrexate to suppress your immune system. This helps to keep the T cells down and so stops them attacking your body cells.
In some cases, you may have a chemotherapy drug called cyclophosphamide after a stem cell transplant. This is more likely after a half matched transplant from a family member, usually a parent or child. This is called a haploidentical transplant. The donor is a 50% match with the person having the transplant.
Before the transplant, you have chemotherapy to lower your immune system. These are usually lower doses of chemotherapy than in a traditional stem cell transplant. This is called reduced intensity conditioning. A few days after the transplant, you have a high dose of cyclophosphamide. The donor's immune cells recognise your body cells as foreign, and start to multiply to attack them. The cyclophosphamide kills these rapidly growing immune cells, and so stops them attacking your body cells. This reduces side effects such as GVHD. You may have this treatment as part of a clinical trial.
Rated 5 out of 5 based on 8 votes
Question about cancer? Contact our information nurse team